HUBBARD ROBERT GLENN 4
4 · METLIFE INC · Filed Mar 12, 2026
Research Summary
AI-generated summary of this filing
MetLife (MET) Director Robert Glenn Hubbard Receives 771-Share Award
What Happened
Robert Glenn Hubbard, a director of MetLife, acquired 771 shares on 2026-03-10 at an imputed price of $70.60 per share, valued at $54,433. The transaction is reported as an award/acquisition (code A) and reflects deferred shares becoming payable under MetLife’s director deferred compensation arrangements.
Key Details
- Transaction date: 2026-03-10; Filing date: 2026-03-12 (Form 4 accession 0001283051-26-000005).
- Price and value: 771 shares × $70.60 = $54,433.
- Transaction type: A (award/acquisition) — imputed reinvestment of dividends on deferred shares.
- Shares owned after the transaction: not specified in the provided filing excerpt.
- Footnote: F1 states these are deferred shares (MetLife common stock that became payable but were deferred) credited via imputed dividend reinvestment under the MetLife Deferred Compensation Plan for Non-Management Directors.
- Timeliness: Filing appears timely (transaction reported two days after the trade date).
Context
This was not an open-market purchase but a crediting of deferred shares tied to the director compensation plan (dividend reinvestment). Such awards are administrative/compensation events and do not necessarily signal a trading decision or change in company outlook.
Insider Transaction Report
Form 4
METLIFE INCMET
HUBBARD ROBERT GLENN
Director
Transactions
- Award
Common Stock
[F1]2026-03-10$70.60/sh+771$54,433→ 104,630 total
Footnotes (1)
- [F1]Imputed reinvestment of dividends on deferred shares pursuant to the MetLife Deferred Compensation Plan for Non-Management Directors. Deferred shares represent shares of MetLife, Inc. common stock that have become payable, but receipt of which the director has deferred.
Signature
/s/ Taylor McInerney Jansen, Attorney-in-fact|2026-03-12